“I remember asking the doctor if my daughter was going to die,” said Chelsea Oakley, mother of Cora Oakley, a newborn who was diagnosed with ADA-SCID when she was just seven days old, in April 2017.

GAITHERSBURG, Md.--(BUSINESS WIRE)--Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S.

A long-term follow-up study tracking a group of children who received experimental gene therapy as part of an early-stage clinical trial is reporting the treatment is safe and effective up to 10 years ...

BOSTON and LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data published in the New England Journal of Medicine (NEJM) ...

Overall and event-free survival of 100 and 95%, respectively, seen with autologous CD34+ hematopoietic stem-cell lentiviral gene therapy. HealthDay News — Autologous CD34+ hematopoietic stem-cell ...

We investigated the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) due to the lack of adenosine deaminase (ADA), a fatal disorder of purine metabolism and ...

While my training includes many therapeutic approaches informed by research, I see therapy most of all as a creative process that unfolds within a genuine relationship. I believe that good therapy is ...

SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, announces the publication of a prospective, cross-sectional ...

August 12, 2011 — The Commission on Dental Accreditation (CODA), an arm of the American Dental Association (ADA), will develop standards for programs that train dental therapists, the commission ...